

Special Issue

Diabetes Mellitus: Pharmacological Innovations and Related Therapeutic Benefits

Message from the Guest Editor

Modern medical care for people with diabetes mellitus has some distinctive features. First, despite all preventive measures, we have witnessed an accelerated increase in the prevalence of diabetes worldwide. Secondly, there have been extraordinary advancements in diabetes-targeting therapies in recent years, with multiple new therapeutic classes and novel technologies being developed to modify the clinical outcomes of people with diabetes. The fundamentals of diabetes care currently extend well beyond glucose control to weight control, encompass a multifactorial approach to cardiovascular risk, and promote the use of antihyperglycemic medications that also offer cardiorenal benefits. Together with the ever-present need to empower patients to successfully self-manage their disease, all these approaches will hopefully change the quality of life and disease duration for millions of people worldwide. Therefore, this Special Issue focuses on these significant advancements, starting from the first phases of pharmacological research on diabetes and extending to the various benefits we see developing regarding the clinical outcomes of people with diabetes.

Guest Editor

Dr. Cristina-Mihaela Lăcătușu

Unit of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine,
"Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași,
Romania

Deadline for manuscript submissions

closed (31 July 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/222009

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).